Quantcast

Latest advanced prostate cancer Stories

2009-09-23 07:00:00

SAN FRANCISCO, Sept. 23 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced treatment of the first patient in a Phase 3 clinical trial of the investigational drug MDV3100 in advanced prostate cancer. Known as AFFIRM, the trial will evaluate the novel androgen receptor antagonist MDV3100 in men with castration-resistant prostate cancer who were previously treated with docetaxel-based chemotherapy. "Late stage prostate cancer remains an obvious and large unmet...

2009-08-10 14:49:00

SEATTLE and ATLANTA, Aug. 10 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced it has signed a lease agreement with Majestic Realty Co. to build a 160,000 square-foot manufacturing facility in Union City, Ga., where it expects to manufacture PROVENGE(R) (sipuleucel-T) for patients with advanced prostate cancer. The state of Georgia will be hosting a ribbon-cutting ceremony on September 30. If approved by the U.S. Food and Drug Administration (FDA), Dendreon...

2009-08-04 07:55:00

PARSIPPANY, N.J., Aug. 4 /PRNewswire/ -- Ferring Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has approved the trade name FIRMAGON(R) (degarelix for injection) for its prostate cancer treatment previously marketed under the generic name degarelix. FIRMAGON is a new injectable gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for patients with advanced prostate cancer. Since initial market introduction under the generic name degarelix,...

2009-06-01 07:00:00

KVISTGAARD, Denmark, June 1 /PRNewswire-FirstCall/ -- Detailed data from a randomized Phase 2 study with PROSTVAC(TM) were presented Saturday at the ASCO Annual Meeting in Orlando. The presentation was made by Philip Kantoff MD, Professor of Medicine, Harvard Medical School, and the Dana-Farber Cancer Institute who is also the principal investigator of the study. The more detailed analysis supports the headline data that were reported in October 2008. In the Phase 2 prospective...

2009-04-28 13:00:00

- Extended Median Survival by 4.1 Months and Increased 3-Year Survival by 38 Percent Compared to Placebo - - First Active Cellular Immunotherapy for Cancer to Prolong Survival - - Company to Host Webcast at 5:30 pm ET - CHICAGO and SEATTLE, April 28 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that its pivotal Phase 3 IMPACT study of PROVENGE(R) (sipuleucel-T) in men with advanced prostate cancer met its primary endpoint of significantly improving overall...

2009-04-28 05:00:00

FDA confirms durable pain palliation as an acceptable primary endpoint for a regulatory submission in support of market approval BOTHELL, WA, April 28 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the company has reached an agreement with the U.S. Food and Drug Administration (FDA) on the design of a second Phase 3 registration trial of OGX-011, its lead product candidate targeting castrate resistant prostate cancer (CRPC), via the...

2009-04-14 07:30:00

- Study Meets Primary Endpoint Showing Statistically Significant Improvement in Overall Survival - - First Active Immunotherapy for Cancer to Prolong Survival - - Full Data to be Presented at Plenary Session at Upcoming AUA Annual Meeting - - Company to Host a Conference Call Today at 9:00 AM ET - SEATTLE, April 14 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) announced today that the pivotal Phase 3 IMPACT study of PROVENGE(R) (sipuleucel-T) in men with advanced prostate...

2009-03-25 10:41:40

Omega-3 fatty acids appear protective against advanced prostate cancer and this effect may be modified by a genetic variant, U.S. researchers said. Previous research has shown protection against prostate cancer but this is one of the first studies to show protection against advanced prostate cancer and interaction with the COX-2 gene, John S. Witte of the University of California San Francisco said in a statement. The researchers performed a case-control analysis of 466 men diagnosed with...

2009-03-25 09:39:45

For the first time, researchers have found something that can protect against advanced prostate cancer, and it's as simple as choosing the right things to eat. Omega-3 fatty acids, especially the kind found in dark fish such as salmon, appear to significantly reduce the risk of advanced prostate cancer. This even proved to be true for men who carried the COX-2 gene, a known inflammatory gene. Scientists gave food questionnaires to 466 men diagnosed with aggressive prostate cancer and 478...

2009-02-25 07:00:00

MOUNTAIN VIEW, California, February 25 /PRNewswire/ -- BN ImmunoTherapeutics, Inc. announced today that the first detailed data on PROSTVAC(TM) since the vaccine was licensed from the National Institutes of Health (NIH) is now available. The data, that once again confirms the excellent safety and efficacy results previously reported, will be presented at the 2009 Genitourinary Cancers Symposium (GU) on February 26-28, 2009 in Orlando, Florida. Abstracts from three different studies,...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related